Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | CCR1 | P32246 | 2/20 | 0.52 |
| ▸ | CCR5 | P51681 | 2/20 | 0.52 |
| ▸ | CCR8 | P51685 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | METAP1 | P53582 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.52 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.50 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.50 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29723603 | 1.00 | KDM4E (0.52) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL3257828 | 0.90 | CYP2A6 (0.55) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL4359878 | 0.82 | CCR1 (0.51) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL21562299 | 0.77 | CYP2A6 (0.42) | NPC1CYP2A6CYP2B6CHRNA7RAB9A | |
| SCHEMBL7470097 | 0.76 | CYP2A6 (0.50) | NPC1CYP2A6CYP2B6CYP2E1CHRNA7 | |
| Thiophene SCHEMBL27789802 | 0.75 | KDM4E (0.52) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL1566968 | 0.74 | KDM4E (0.72) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL30989133 | 0.74 | KDM4E (0.72) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL30989132 | 0.74 | KDM4E (0.72) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL1445303 | 0.73 | CYP11B1 (0.44) | NPC1CYP2A6CYP2B6CYP2E1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115379-B2 | Use of metal complexes as emitter in an organic light-emitting component and such a component | NOVALED AG (DE) | 2012-02-14 | — | — | US | claimed |
| US-20090318698-A1 | Use of Metal Complexes as Emitter in an Organic Light-Emitting Component and such a Component | NOVALED AG (DE) | 2009-12-24 | — | — | US | claimed |
| US-20020025477-A1 | Non-aqueous electrolytic solution and secondary battery containing same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2002-02-28 | — | — | US | claimed |
| EP-1172878-A2 | Non-aqueous electrolytic solution and secondary battery containing same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2002-01-16 | — | — | EP | claimed |
| CN-114269756-B | 4-Oxo-3, 4-dihydropyrido [3,4-D ] pyrimidine compounds that inhibit EIF4E | 效应疗法股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-114667280-A | Acrylamide compound | 大塚制药株式会社 | 2022-06-24 | — | — | CN | disclosed |
| CN-114269756-A | 4-oxo-3, 4-dihydropyrido [3,4-D ] pyrimidine compounds inhibiting EIF4E | 效应疗法股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-107207472-A | Inhibitors of AKT kinase | 卑尔根生物股份公司 | 2017-09-26 | — | — | CN | disclosed |
| CN-104755460-B | N-acylhydrazone derivatives for selective T cell inhibitor and anti-lymphoid malignancy drug | 株式会社钟根堂 | 2017-05-10 | — | — | CN | disclosed |
| CN-104011046-B | Aminopyrimidine kinase inhibitors | 嘉世高制药公司 | 2017-05-03 | — | — | CN | disclosed |
| US-20150373978-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS PESTICIDES | BAYER IP GMBH (DE) | 2015-12-31 | — | — | US | disclosed |
| US-9173396-B2 | Heterocyclic compounds as pesticides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-03 | — | — | US | disclosed |
| CN-1158854-A | Borate cointiators for photopolymerization | CIBA GEIGY AG (CH) | 1997-09-10 | — | — | CN | disclosed |
| EP-0165753-B1 | HERBICIDAL THIOPHENESULFONAMIDES AND PYRIDINESULFONAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-12-11 | — | — | EP | disclosed |
| EP-0175541-B1 | AMINOALKOXYBENZOPYRANONES AND PROCESSES FOR THE PRODUCTION THEREOF | WARNER-LAMBERT COMPANY (US) | 1989-02-22 | — | — | EP | disclosed |
| US-4723988-A | PLANT GROWTH REGULATORS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-02-09 | — | — | US | disclosed |
| US-4701456-A | SCHIZOPHRENIA | WARNER-LAMBERT COMPANY (US) | 1987-10-20 | — | — | US | disclosed |
| US-4684393-A | PLATN GROWTH REGULATORS | E. I. DUPONT DE NEMOURS AND COMPANY (US) | 1987-08-04 | — | — | US | disclosed |
| EP-0175541-A1 | Aminoalkoxybenzopyranones and processes for the production thereof | WARNER-LAMBERT COMPANY (US) | 1986-03-26 | — | — | EP | disclosed |
| EP-0165753-A2 | Herbicidal thiophenesulfonamides and pyridinesulfonamides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318698-A1 | Use of Metal Complexes as Emitter in an Organic Light-Emitting Component and such a Component | CACNG2, CACNG3, CACNG4 | KDM4E 1339/4885LMNA 992/4885CCR1 3826/4885 |
| US-20150373978-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS PESTICIDES | DDT, ACHE, PTMS | KDM4E 1664/4885LMNA 2977/4885CCR1 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.